Cargando…

How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?

The current pandemic coronavirus, SARS-CoV-2, is known to cause severe infection (COVID-19) in patients with comorbidities, particularly cancer or an immunosuppressed state. Most healthcare systems in the country are likely to be overwhelmed soon if the pandemic moves to a stage of community transmi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Arihant, Singh, Charanpreet, Dhawan, Rishi, Jindal, Nishant, Mohindra, Ritin, Lad, Deepesh, Prakash, Gaurav, Khadwal, Alka, Suri, Vikas, Bhalla, Ashish, Kumari, Savita, Varma, Neelam, John, M Joseph, Mahapatra, Manoranjan, Malhotra, Pankaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274942/
https://www.ncbi.nlm.nih.gov/pubmed/32837051
http://dx.doi.org/10.1007/s12288-020-01300-0
_version_ 1783542677642412032
author Jain, Arihant
Singh, Charanpreet
Dhawan, Rishi
Jindal, Nishant
Mohindra, Ritin
Lad, Deepesh
Prakash, Gaurav
Khadwal, Alka
Suri, Vikas
Bhalla, Ashish
Kumari, Savita
Varma, Neelam
John, M Joseph
Mahapatra, Manoranjan
Malhotra, Pankaj
author_facet Jain, Arihant
Singh, Charanpreet
Dhawan, Rishi
Jindal, Nishant
Mohindra, Ritin
Lad, Deepesh
Prakash, Gaurav
Khadwal, Alka
Suri, Vikas
Bhalla, Ashish
Kumari, Savita
Varma, Neelam
John, M Joseph
Mahapatra, Manoranjan
Malhotra, Pankaj
author_sort Jain, Arihant
collection PubMed
description The current pandemic coronavirus, SARS-CoV-2, is known to cause severe infection (COVID-19) in patients with comorbidities, particularly cancer or an immunosuppressed state. Most healthcare systems in the country are likely to be overwhelmed soon if the pandemic moves to a stage of community transmission. Currently, limited evidence is available for managing patients with hematological disorders during the COVID-19 pandemic. The current review summarises the possible challenges clinicians are likely to face, key considerations to guide decision making, and possible solutions to the anticipated challenges. Disease specific recommendations and possible guidance for decision making have been suggested for most hematologic diseases that are feasible in our health setup. It is not meant to replace individual clinical judgment, but to provide a template to formulate local policies.
format Online
Article
Text
id pubmed-7274942
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-72749422020-06-08 How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India? Jain, Arihant Singh, Charanpreet Dhawan, Rishi Jindal, Nishant Mohindra, Ritin Lad, Deepesh Prakash, Gaurav Khadwal, Alka Suri, Vikas Bhalla, Ashish Kumari, Savita Varma, Neelam John, M Joseph Mahapatra, Manoranjan Malhotra, Pankaj Indian J Hematol Blood Transfus Review Article The current pandemic coronavirus, SARS-CoV-2, is known to cause severe infection (COVID-19) in patients with comorbidities, particularly cancer or an immunosuppressed state. Most healthcare systems in the country are likely to be overwhelmed soon if the pandemic moves to a stage of community transmission. Currently, limited evidence is available for managing patients with hematological disorders during the COVID-19 pandemic. The current review summarises the possible challenges clinicians are likely to face, key considerations to guide decision making, and possible solutions to the anticipated challenges. Disease specific recommendations and possible guidance for decision making have been suggested for most hematologic diseases that are feasible in our health setup. It is not meant to replace individual clinical judgment, but to provide a template to formulate local policies. Springer India 2020-06-06 2020-10 /pmc/articles/PMC7274942/ /pubmed/32837051 http://dx.doi.org/10.1007/s12288-020-01300-0 Text en © Indian Society of Hematology and Blood Transfusion 2020
spellingShingle Review Article
Jain, Arihant
Singh, Charanpreet
Dhawan, Rishi
Jindal, Nishant
Mohindra, Ritin
Lad, Deepesh
Prakash, Gaurav
Khadwal, Alka
Suri, Vikas
Bhalla, Ashish
Kumari, Savita
Varma, Neelam
John, M Joseph
Mahapatra, Manoranjan
Malhotra, Pankaj
How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
title How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
title_full How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
title_fullStr How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
title_full_unstemmed How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
title_short How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
title_sort how to use a prioritised approach for treating hematological disorders during the covid-19 pandemic in india?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274942/
https://www.ncbi.nlm.nih.gov/pubmed/32837051
http://dx.doi.org/10.1007/s12288-020-01300-0
work_keys_str_mv AT jainarihant howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia
AT singhcharanpreet howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia
AT dhawanrishi howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia
AT jindalnishant howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia
AT mohindraritin howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia
AT laddeepesh howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia
AT prakashgaurav howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia
AT khadwalalka howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia
AT surivikas howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia
AT bhallaashish howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia
AT kumarisavita howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia
AT varmaneelam howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia
AT johnmjoseph howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia
AT mahapatramanoranjan howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia
AT malhotrapankaj howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia